Worldcoin desafía la tendencia bajista con un alza del 12.95% en 24 horas Ivar AI

Diariobitcoin.com

Audiera ($BEAT) explota un 91% en 24 horas y supera los USD 4 el 8 de junio de 2026

CBS News

U.S. launches more strikes on Iranian targets after Trump promises to hit Iran "hard"

The Times of India

Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapse

Diariobitcoin.com

Audiera ($BEAT) desafía la gravedad: ¿burbuja o nuevo paradigma cripto?

Noticiabrasil.net.br

Estados Unidos voltam a atacar Irã após queda de helicóptero no estreito de Ormuz

Crypto Briefing

US military launches airstrikes against Iran after helicopter downing near Strait of Hormuz

SiliconANGLE News

Neura Robotics to raise up to $1.4B from Nvidia-backed consortium

CBS News

OpenAI says it filed confidential IPO as it positions itself for AI arms race

The Times of India

Citi leverages AI to transform payments, boost efficiency and enhance cross-border transactions

Crypto Briefing

Pentagon adds Alibaba, Baidu, and BYD to military-linked list, expanding it to 188 entities

Yahoo Entertainment

美軍空襲伊朗反擊直升機事件中東局勢動盪衝擊油市

El Mundo

Las claves del nuevo enfrentamiento de Irán e Israel con Líbano como detonador

The Times of India

U.S. spending on rebuilding nuclear arsenal more than all other nuclear states combined including China, Russia

Crypto Briefing

SpaceX IPO oversubscribed at $150B in demand as largest-ever listing nears

Macdailynews.com

Apple’s iPhone momentum shines bright: 19.7% YoY production surge positions it for market leadership amid industry headwinds

Diariobitcoin.com

Audiera ($BEAT) se dispara un 65% en un solo día y toca los USD $2,99

Yahoo Entertainment

幫馬斯克撈火箭！27歲的她有望變億萬富豪　靠「1大膽決定」迎SpaceX上市

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire